Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Centre International De Recherches Dermatologiques Galderma

Galderma Research & Development Snc

C.i.r.d. Galderma

Centre International De Recherches Dermatologioues Galderma (c.i.r.d. Galderma)

Laszlo Fesus

Uwe Reichert

Zsuzsa Szondy

Gabor Kovacs

Istvan Szekely

Sandor Botar

Peter S Kormoczy

Marianna Lovasz Nee Gaspar

Karoly Horvath

Pal Hadhazy

Krisztina Kekesi

Istvan Rakoczy

The present invention relates to pharmaceutical and cosmetic compositions comprising at least one agonist ligand, which is specific for receptors of the RAR-&ggr; type, which are characterized as inducers of apoptosis in at least one cell population in which apoptosis can be induced by activating receptors of the RAR-&ggr; type. In one aspect of the present invention, there is provided a method of combating photoinduced or chronological ageing of skin, said method comprising administering an effective amount of at least one agonist ligand which is specific for receptors of the RAR-&ggr; type to combat photoinduced or chronological aging of skin, wherein the agonist ligand has a ratio R which is equal to or greater than 10.

Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis

The use of at least one &ggr;-RAR receptor-specific agonist ligand to prepare a pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating &ggr;-RAR receptors is disclosed. The composition is particularly useful for treating a disease or disorder related to an insufficient rate of apoptosis in at least one cell population in which apoptosis may be induced by activating &ggr;-RAR receptors. The use of at least one &ggr;-RAR receptor-specific agonist ligand as the apoptosis inducer in a cosmetic composition is also disclosed. Said composition may be used to prevent and/or control photo-ageing or chronological ageing of the skin.

Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthanoic acid.

.gamma.-RAR antagonist ligand or .alpha.-RAR agonist ligand as an

The invention relates to new, 7-substituted PGI.sub.2 -derivatives of formula (I) ##STR1## The new compounds have valuable therapeutical properties, and in particular show prostacyclin-like effects.

7-Substituted PGI.sub.2 -derivatives and pharmaceutical compositions

Growing community of inventors

Debrecen, Hungary

Laszlo Fesus